Rachel F Tyndale

List of Publications by Year
in descending order

360 papers	17,617 citations	13827 67 h-index	23472 111 g-index
365 all docs	365 docs citations	365 times ranked	14068 citing authors

#	Article	IF	Citations
1	Guidelines on nicotine dose selection for in vivo research. Psychopharmacology, 2007, 190, 269-319.	1.5	694
2	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature Genetics, 2017, 49, 1126-1132.	9.4	472
3	Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. Clinical Pharmacology and Therapeutics, 2004, 76, 64-72.	2.3	366
4	Nicotine metabolism defect reduces smoking. Nature, 1998, 393, 750-750.	13.7	359
5	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	0.7	341
6	Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics and Genomics, 2004, 14, 615-626.	5.7	279
7	Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 131-138.	5.2	247
8	Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics, 2006, 79, 600-608.	2.3	242
9	Nicotine-dependence symptoms are associated with smoking frequency in adolescents. American Journal of Preventive Medicine, 2003, 25, 219-225.	1.6	236
10	Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*. Clinical Pharmacology and Therapeutics, 2005, 77, 145-158.	2.3	231
11	Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. Drug Metabolism and Disposition, 2002, 30, 314-318.	1.7	223
12	Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking. Molecular Pharmacology, 2000, 58, 747-755.	1.0	222
13	Genetics of alcohol and tobacco use in humans. Annals of Medicine, 2003, 35, 94-121.	1.5	206
14	Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in Pharmacological Sciences, 2011, 32, 708-714.	4.0	205
15	The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [3H]GBR-12935 binding proteins. Archives of Biochemistry and Biophysics, 1990, 276, 424-432.	1.4	203
16	Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Pharmacology Biochemistry and Behavior, 2009, 92, 6-11.	1.3	200
17	Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology, 2003, 45, 122-132.	2.0	188
18	CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology and Therapeutics, 2006, 80, 457-467.	2.3	184

#	Article	IF	Citations
19	Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 Variation and Smoking Behaviors and Lung Cancer Risk. Journal of the National Cancer Institute, 2011, 103, 1342-1346.	3.0	168
20	Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics and Genomics, 1991, 1, 26-32.	5.7	152
21	Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics, 2000, 68, 35-43.	2.3	146
22	Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African-American Light Smokers. Clinical Pharmacology and Therapeutics, 2009, 85, 635-643.	2.3	146
23	Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (Cambridge), 2013, 140, 3285-3296.	1.2	138
24	Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics and Genomics, 1997, 7, 375-379.	5.7	131
25	Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. Journal of Neurochemistry, 2002, 82, 1376-1387.	2.1	129
26	Evidence of Association between Smoking and Î±7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients. Neuropsychopharmacology, 2004, 29, 1522-1526.	2.8	129
27	Nicotinic acetylcholine receptor Î²2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics, 2008, 17, 2834-2848.	1.4	129
28	The Role of CYP2A6 in the Emergence of Nicotine Dependence in Adolescents. Pediatrics, 2007, 119, e264-e274.	1.0	125
29	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	2.3	125
30	The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics. Drug Metabolism Reviews, 2004, 36, 313-333.	1.5	124
31	CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial. Biological Psychiatry, 2007, 62, 635-641.	0.7	124
32	Drug-metabolizing cytochrome P450s in the brain. Journal of Psychiatry and Neuroscience, 2002, 27, 406-15.	1.4	120
33	Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. British Journal of Pharmacology, 2003, 138, 1376-1386.	2.7	119
34	Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior. Therapeutic Drug Monitoring, 2002, 24, 163-171.	1.0	118
35	CYP2A6 genetic variation and potential consequences. Advanced Drug Delivery Reviews, 2002, 54, 1245-1256.	6.6	118
36	Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci. Clinical Epigenetics, 2019, 11, 1.	1.8	116

#	Article	IF	Citations
37	A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature, 1993, 364, 448-450.	13.7	114
38	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 695-708.	0.7	114
39	Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochemical Pharmacology, 2000, 59, 1501-1511.	2.0	113
40	Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of Neurochemistry, 2006, 98, 1866-1875.	2.1	113
41	Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes. Journal of Neurogenetics, 2009, 23, 252-261.	0.6	111
42	PharmVar GeneFocus: CYP2B6. Clinical Pharmacology and Therapeutics, 2021, 110, 82-97.	2.3	108
43	A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. PLoS Genetics, 2015, 11, e1005498.	1.5	107
44	Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures. Annals of the New York Academy of Sciences, 2000, 914, 394-401.	1.8	106
45	Cytochrome P450â€“mediated drug metabolism in the brain. Journal of Psychiatry and Neuroscience, 2013, 38, 152-163.	1.4	103
46	Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 234-238.	1.1	101
47	Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1773-1782.	1.1	101
48	Genetic variability inCYP2A6and the pharmacokinetics of nicotine. Pharmacogenomics, 2007, 8, 1385-1402.	0.6	100
49	Variation in CYP2A6 Activity and Personalized Medicine. Journal of Personalized Medicine, 2017, 7, 18.	1.1	99
50	The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 660-666.	1.1	97
51	Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. International Journal of Epidemiology, 2004, 33, 971-978.	0.9	96
52	Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1105-1114.	1.1	96
53	Intercellular Calcium Waves in Neurons. Molecular and Cellular Neurosciences, 1996, 7, 337-353.	1.0	95
54	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics and Genomics, 2001, 11, 477-487.	5.7	90

#	Article	IF	Citations
55	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics and Genomics, 1998, 8, 325-333.	5.7	85
56	Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics, 2013, 23, 94-103.	0.7	85
57	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics and Genomics, 1998, 8, 305-313.	5.7	82
58	Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA/2 and C57BL/6 Mice. Molecular Pharmacology, 2007, 71, 826-834.	1.0	80
59	Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology, 2005, 178, 183-192.	1.5	79
60	An association of CYP2A6 genotype and smoking topography. Nicotine and Tobacco Research, 2007, 9, 511-518.	1.4	78
61	The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 708-718.	1.1	77
62	Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. Journal of the National Cancer Institute, 2012, 104, 290-298.	3.0	74
63	Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today, 2003, 8, 487-493.	3.2	72
64	Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology, 2008, 55, 1147-1155.	2.0	72
65	Genetic and environmental influences on the ratio of 3â€²hydroxycotinine to cotinine in plasma and urine. Pharmacogenetics and Genomics, 2009, 19, 388-398.	0.7	72
66	CYP2B6 and Bupropionâ€™s Smoking-Cessation Pharmacology: The Role of Hydroxybupropion. Clinical Pharmacology and Therapeutics, 2012, 92, 771-777.	2.3	72
67	Chapter 8 Ibogaine in the treatment of heroin withdrawal. The Alkaloids Chemistry and Biology, 2001, 56, 155-171.	0.8	71
68	Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology, 2006, 184, 401-408.	1.5	71
69	Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. PLoS ONE, 2015, 10, e0137070.	1.1	71
70	Non-Nicotinic Therapies for Smoking Cessation. Annual Review of Pharmacology and Toxicology, 2007, 47, 541-564.	4.2	69
71	Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human Mutation, 2008, 29, 679-688.	1.1	69
72	Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenetics and Genomics, 2005, 15, 115-125.	0.7	68

#	Article	IF	Citations
73	The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiology of Aging, 2012, 33, 2160-2171.	1.5	68
74	Genetic Relationship between Schizophrenia and Nicotine Dependence. Scientific Reports, 2016, 6, 25671.	1.6	67
75	Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug and Alcohol Dependence, 2007, 89, 24-33.	1.6	66
76	The Human Dopamine D5 Receptor Gene: Cloning and Characterization of the 5'-Flanking and Promoter Region. Biochemistry, 1995, 34, 5960-5970.	1.2	65
77	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1239-1246.	1.1	65
78	Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. International Journal of Epidemiology, 2015, 44, 1537-1546.	0.9	62
79	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nature Communications, 2018, 9, 3221.	5.8	60
80	The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine and Tobacco Research, 2003, 5, 891-899.	1.4	59
81	Cytochromeâ€ƒP450â€ƒ2D6 enzyme neuroprotects against 1â€•methylâ€4â€•phenylpyridinium toxicity in SHâ€SY5Y neuronal cells. European Journal of Neuroscience, 2010, 31, 1185-1193.	1.2	59
82	CYP-mediated drug metabolism in the brain impacts drug response. , 2018, 184, 189-200.		59
83	Potential role of CYP2D6 in the central nervous system. Xenobiotica, 2013, 43, 973-984.	0.5	58
84	CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenetics and Genomics, 2013, 23, 232-235.	0.7	58
85	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [¹¹C]CURB. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1237-1240.	2.4	58
86	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Canadian Journal of Physiology and Pharmacology, 2001, 79, 841-847.	0.7	57
87	Reduced (Â±)-3,4-methylenedioxymethamphetamine (â€œEcstasyâ€) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemical Pharmacology, 2002, 63, 2111-2119.	2.0	57
88	Down-Regulation of Hepatic Nicotine Metabolism and a CYP2A6-Like Enzyme in African Green Monkeys after Long-Term Nicotine Administration. Molecular Pharmacology, 2003, 63, 96-104.	1.0	57
89	CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1812-1819.	1.1	57
90	Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochimica Et Biophysica Acta - General Subjects, 2003, 1619, 283-290.	1.1	55

#	Article	IF	Citations
91	Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. European Journal of Clinical Pharmacology, 2010, 66, 239-251.	0.8	55
92	Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenetics and Genomics, 2013, 23, 135-141.	0.7	55
93	The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology, 2014, 231, 2515-2523.	1.5	55
94	The role of pharmacogenetically-variable cytochrome P450 enzymes in. Pharmacogenomics, 2002, 3, 185-199.	0.6	53
95	Nicotine Pharmacokinetics in Rats Is Altered as a Function of Age, Impacting the Interpretation of Animal Model Data. Drug Metabolism and Disposition, 2014, 42, 1447-1455.	1.7	53
96	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. Biological Psychiatry, 2016, 80, 691-701.	0.7	53
97	Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology, 2008, 198, 181-190.	1.5	52
98	Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition. Neuropsychopharmacology, 2009, 34, 634-640.	2.8	52
99	Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. Journal of the National Cancer Institute, 2019, 111, 1078-1087.	3.0	52
100	Molecular Genetics of Nicotine Metabolism. Handbook of Experimental Pharmacology, 2009, , 235-259.	0.9	52
101	INTERACTION OF BUPRENORPHINE AND ITS METABOLITE NORBUPRENORPHINE WITH CYTOCHROMES P450 IN VITRO. Drug Metabolism and Disposition, 2003, 31, 768-772.	1.7	51
102	Rat Brain CYP2B-Enzymatic Activation of Chlorpyrifos to the Oxon Mediates Cholinergic Neurotoxicity. Toxicological Sciences, 2012, 126, 325-335.	1.4	51
103	Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. Pharmacology Biochemistry and Behavior, 2016, 148, 1-7.	1.3	51
104	CYP2E1*1D regulatory polymorphism. Pharmacogenetics and Genomics, 2003, 13, 321-328.	5.7	50
105	A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenetics and Genomics, 2008, 18, 67-75.	0.7	50
106	Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. Nicotine and Tobacco Research, 2002, 4, 423-431.	1.4	49
107	Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers. Clinical Pharmacology and Therapeutics, 2014, 96, 256-265.	2.3	49
108	Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. Biology of Sex Differences, 2020, 11, 8.	1.8	49

#	Article	IF	Citations
109	Altered GABAA Receptor Subunit and Splice Variant Expression in Rats Treated With Chronic Intermittent Ethanol. Alcoholism: Clinical and Experimental Research, 2001, 25, 819-828.	1.4	48
110	Identification of Novel CYP2A6*1B Variants: The CYP2A6*1B Allele is Associated With Faster In Vivo Nicotine Metabolism. Clinical Pharmacology and Therapeutics, 2008, 83, 115-121.	2.3	48
111	Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics and Genomics, 2001, 11, 85-94.	5.7	47
112	Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica, 2010, 40, 381-392.	0.5	46
113	Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction, 2011, 106, 985-994.	1.7	46
114	Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers. Psychopharmacology, 2018, 235, 193-202.	1.5	46
115	Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism. Journal of Clinical Psychopharmacology, 1998, 18, 332-337.	0.7	46
116	Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability. Journal of Clinical Psychopharmacology, 2000, 20, 435-444.	0.7	46
117	Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. Journal of Psychiatry and Neuroscience, 2008, 33, 54-63.	1.4	46
118	HUMAN CYP2D6 AND MOUSE CYP2DS: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL. Drug Metabolism and Disposition, 2005, 33, 1495-1502.	1.7	45
119	Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. NeuroImage, 2012, 60, 2136-2143.	2.1	45
120	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis, 2013, 34, 93-101.	1.3	45
121	Rate of Nicotine Metabolism and Smoking Cessation Outcomes in a Community-based Sample of Treatment-Seeking Smokers. Addictive Behaviors, 2015, 51, 93-99.	1.7	45
122	Genomeâ€wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction, 2018, 113, 509-523.	1.7	45
123	Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. Molecular Psychiatry, 2021, 26, 2212-2223.	4.1	45
124	Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. Psychology of Addictive Behaviors, 2019, 33, 105-116.	1.4	45
125	INDUCTION AND RECOVERY TIME COURSE OF RAT BRAIN CYP2E1 AFTER NICOTINE TREATMENT. Drug Metabolism and Disposition, 2006, 34, 647-652.	1.7	44
126	Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects. Neuropsychopharmacology, 2011, 36, 692-700.	2.8	44

#	Article	IF	Citations
127	Effect of a Nicotine Vaccine on Nicotine Binding to Î²₂*-Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco Smokers. American Journal of Psychiatry, 2013, 170, 399-407.	4.0	44
128	Rat Hepatic CYP2E1 Is Induced by Very Low Nicotine Doses: An Investigation of Induction, Time Course, Dose Response, and Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 941-947.	1.3	42
129	CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology, 2006, 50, 441-450.	2.0	42
130	Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology, 2006, 50, 568-575.	2.0	42
131	CYP2B6 Genotype Does Not Alter Nicotine Metabolism, Plasma Levels, or Abstinence with Nicotine Replacement Therapy. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1312-1314.	1.1	42
132	CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology, 2012, 68, 937-942.	0.8	42
133	Pharmacogenetics of Nicotine and Associated Smoking Behaviors. Current Topics in Behavioral Neurosciences, 2015, 23, 37-86.	0.8	42
134	Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2. Scientific Reports, 2016, 6, 20092.	1.6	42
135	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2020, 107, 57-61.	2.3	42
136	Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. Journal of Neurochemistry, 2006, 96, 1028-1041.	2.1	41
137	Selegiline Is a Mechanism-Based Inactivator of CYP2A6 Inhibiting Nicotine Metabolism in Humans and Mice. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 992-999.	1.3	41
138	Dopamine Genes and Nicotine Dependence in Treatment-Seeking and Community Smokers. Neuropsychopharmacology, 2009, 34, 2252-2264.	2.8	41
139	CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokersâ€"findings from two independent populations. Carcinogenesis, 2015, 36, 99-103.	1.3	41
140	Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers. JAMA Internal Medicine, 2016, 176, 184.	2.6	41
141	Mimicking Gene Defects to Treat Drug Dependence. Annals of the New York Academy of Sciences, 2000, 909, 233-246.	1.8	40
142	Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. PLoS ONE, 2015, 10, e0128109.	1.1	40
143	CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenetics and Genomics, 2012, 22, 429-440.	0.7	39
144	Variation in Trans-3â€²-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. PLoS ONE, 2013, 8, e70938.	1.1	39

#	Article	IF	Citations
145	Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies*. Clinical Pharmacology and Therapeutics, 1998, 64, 378-383.	2.3	38
146	Dopaminergic Signaling Mediates the Motivational Response Underlying the Opponent Process to Chronic but Not Acute Nicotine. Neuropsychopharmacology, 2010, 35, 943-954.	2.8	38
147	Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. Neuropsychopharmacology, 2015, 40, 1804-1812.	2.8	38
148	Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics and Genomics, 2005, 15, 189-192.	0.7	37
149	A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics Journal, 2009, 9, 274-282.	0.9	37
150	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. Twin Research and Human Genetics, 2004, 7, 435-448.	1.5	37
151	Geneâ€“gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenetics and Genomics, 2007, 17, 1007-1015.	0.7	36
152	Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial. Free Radical Biology and Medicine, 2019, 143, 471-481.	1.3	36
153	Differences in the rate of nicotine metabolism among smokers with and without HIV. Aids, 2019, 33, 1083-1088.	1.0	36
154	First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. Biochemical Pharmacology, 2013, 85, 1848-1855.	2.0	35
155	CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. Biological Psychiatry, 2017, 81, 554-563.	0.7	35
156	Pharmacogenetic Optimization of Smoking Cessation Treatment. Trends in Pharmacological Sciences, 2017, 38, 55-66.	4.0	35
157	Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment. Annual Review of Pharmacology and Toxicology, 2010, 50, 39-61.	4.2	34
158	Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain22Abbreviations: CYP, cytochrome P450; C8 xanthate, potassium octylxanthate; NCO, nicotine C-oxidation; NDMA, N-nitrosodimethylamine; NMA, N-nitroso-N-methylaniline; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; and SSC, saline-sodium citrate buffer.. Biochemical Pharmacology, 2001, 62, 1025-1036.	2.0	33
159	Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. Addictive Behaviors, 2013, 38, 1796-1803.	1.7	33
160	Imaging Changes in Synaptic Acetylcholine Availability in Living Human Subjects. Journal of Nuclear Medicine, 2013, 54, 78-82.	2.8	33
161	Exposure to Nicotine and Carcinogens among Southwestern Alaskan Native Cigarette Smokers and Smokeless Tobacco Users. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 934-942.	1.1	32
162	A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine and Tobacco Research, 1999, 1, 63-67.	1.4	31

#	Article	IF	Citations
163	Utility and Relationships of Biomarkers of Smoking in African-American Light Smokers. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3426-3434.	1.1	31
164	New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics, 2010, 11, 189-198.	0.6	31
165	Reduced-Nicotine Cigarettes in Young Smokers: Impact of Nicotine Metabolism on Nicotine Dose Effects. Neuropsychopharmacology, 2017, 42, 1610-1618.	2.8	31
166	Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 129-139.	1.3	31
167	Measures and predictors of varenicline adherence in the treatment of nicotine dependence. Addictive Behaviors, 2017, 75, 122-129.	1.7	31
168	Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction, 2013, 108, 2202-2211.	1.7	30
169	Disposition kinetics and metabolism of nicotine and cotinine in African American smokers. Pharmacogenetics and Genomics, 2016, 26, 340-350.	0.7	30
170	Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. European Journal of Endocrinology, 2011, 165, 961-967.	1.9	29
171	Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenetics and Genomics, 2014, 24, 118-128.	0.7	29
172	Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology, 2014, 85, 67-72.	2.0	28
173	RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. BMC Genomics, 2015, 16, 990.	1.2	28
174	Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. Clinical Pharmacology and Therapeutics, 2019, 105, 641-651.	2.3	28
175	Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. Neuropsychopharmacology, 2020, 45, 1289-1296.	2.8	28
176	Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers. Journal of Clinical Psychopharmacology, 1999, 19, 472-475.	0.7	28
177	High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine: A Proof of Concept Placebo-Controlled Trial. Nicotine and Tobacco Research, 2013, 15, 348-354.	1.4	27
178	Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. Journal of Nuclear Medicine, 2015, 56, 1724-1729.	2.8	27
179	UGT1A and UGT2B Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 94-104.	1.1	27
180	Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. Biological Psychiatry, 2016, 80, 190-197.	0.7	27

#	Article	IF	Citations
181	Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 140-148.	2.5	27
182	CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol. Food Chemistry, 2017, 217, 716-725.	4.2	27
183	Cytochrome P450 2D6 and Treatment of Codeine Dependence. Journal of Clinical Psychopharmacology, 2000, 20, 43-45.	0.7	27
184	Genotyping human CYP2A6 variants. Methods in Enzymology, 2002, 357, 59-69.	0.4	26
185	Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. European Journal of Pharmacology, 2009, 609, 88-95.	1.7	26
186	Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. Pharmacogenetics and Genomics, 2015, 25, 263-269.	0.7	25
187	Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. Addiction Biology, 2020, 25, e12741.	1.4	25
188	Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addiction Science & Clinical Practice, 2010, 5, 17-29.	1.2	25
189	Nicotineâ€motivated behavior in <scp>C</scp>aenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acrâ€5 and acrâ€15. European Journal of Neuroscience, 2013, 37, 743-756.	1.2	24
190	Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. Drug Metabolism and Disposition, 2014, 42, 1971-1977.	1.7	24
191	Ethanol selfâ€administration and nicotine treatment increase brain levels of <scp>CYP</scp>2<scp>D</scp> in <scp>A</scp>frican green monkeys. British Journal of Pharmacology, 2014, 171, 3077-3088.	2.7	24
192	The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. Nicotine and Tobacco Research, 2016, 18, 491-495.	1.4	24
193	Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 238-245.	1.3	24
194	OpenVape: An Open-Source E-Cigarette Vapor Exposure Device for Rodents. ENeuro, 2020, 7, ENEURO.0279-20.2020.	0.9	24
195	Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6. Journal of Clinical Psychopharmacology, 2002, 22, 326-329.	0.7	23
196	Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Human Psychopharmacology, 2010, 25, 71-79.	0.7	23
197	Association of the Nicotine Metabolite Ratio and CHRNA5/CHRNA3 Polymorphisms With Smoking Rate Among Treatment-Seeking Smokers. Nicotine and Tobacco Research, 2011, 13, 498-503.	1.4	23
198	Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. Neuropharmacology, 2013, 72, 74-81.	2.0	23

#	Article	IF	Citations
199	Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Neuropsychopharmacology, 2015, 40, 1910-1918.	2.8	23
200	Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?. Journal of Smoking Cessation, 2017, 12, 63-70.	0.3	23
201	The influence of an endogenous Î²3 subunit on recombinant GABAA receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. Neuropharmacology, 2000, 39, 611-620.	2.0	22
202	A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenetics and Genomics, 2009, 19, 538-551.	0.7	22
203	Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. Nicotine and Tobacco Research, 2014, 16, 18-25.	1.4	22
204	Does cannabis use moderate smoking cessation outcomes in treatmentâ€seeking tobacco smokers? Analysis from a large multiâ€center trial. American Journal on Addictions, 2016, 25, 291-296.	1.3	22
205	Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenetics and Genomics, 2017, 27, 169-178.	0.7	22
206	C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration. Brain Sciences, 2019, 9, 244.	1.1	22
207	Neural basis of smokingâ€induced relief of craving and negative affect: Contribution of nicotine. Addiction Biology, 2019, 24, 1087-1095.	1.4	22
208	Genetic Influences on Smoking. Therapeutic Drug Monitoring, 2005, 27, 704-709.	1.0	21
209	Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. European Journal of Clinical Pharmacology, 2006, 62, 481-484.	0.8	21
210	In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment. Drug Metabolism and Disposition, 2006, 34, 1508-1515.	1.7	21
211	Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials, 2011, 12, 22.	0.7	21
212	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. Nicotine and Tobacco Research, 2014, 16, 1638-1646.	1.4	21
213	Fatty acid amide hydrolase is lower in young cannabis users. Addiction Biology, 2021, 26, e12872.	1.4	21
214	CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics and Genomics, 2003, 13, 321-8.	5.7	21
215	CYP2D6 phenotype and genotype in a Canadian native indian population. Pharmacogenetics and Genomics, 1997, 7, 145-148.	5.7	20
216	Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. Journal of Psychopharmacology, 2006, 20, 7-14.	2.0	20

#	Article	IF	Citations
217	Differences in pharmacogenetics of nicotine and alcohol metabolism: Review and recommendations for future research. Nicotine and Tobacco Research, 2007, 9, 459-474.	1.4	20
218	Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. PLoS ONE, 2015, 10, e0126113.	1.1	20
219	Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. Nicotine and Tobacco Research, 2015, 17, 1167-1172.	1.4	20
220	CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms. Pharmacogenomics, 2016, 17, 147-162.	0.6	20
221	Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. Pharmacogenetics and Genomics, 2018, 28, 7-16.	0.7	20
222	Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. Trends in Molecular Medicine, 2018, 24, 187-196.	3.5	20
223	Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers. JAMA Network Open, 2018, 1, e181346.	2.8	20
224	Metabolism of 18-Methoxycoronaridine, an Ibogaine Analog, to 18-Hydroxycoronaridine by Genetically Variable CYP2C19. Drug Metabolism and Disposition, 2002, 30, 663-669.	1.7	19
225	Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Research, 2010, 1348, 1-9.	1.1	19
226	Addressing the instability issue of dopamine during microdialysis: the determination of dopamine, serotonin, methamphetamine and its metabolites in rat brain. Journal of Chromatography A, 2020, 1627, 461403.	1.8	19
227	Developmental Hippocampal Neuroplasticity in a Model of Nicotine Replacement Therapy during Pregnancy and Breastfeeding. PLoS ONE, 2012, 7, e37219.	1.1	18
228	Infusion of brainâ€derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation. European Journal of Neuroscience, 2013, 37, 996-1003.	1.2	18
229	The DRD4 Exon III VNTR, Bupropion, and Associations With Prospective Abstinence. Nicotine and Tobacco Research, 2013, 15, 1190-1200.	1.4	18
230	Effect of food training and training dose on nicotine self-administration in rats. Behavioural Brain Research, 2014, 274, 10-18.	1.2	18
231	Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. Drug and Alcohol Dependence, 2016, 158, 139-146.	1.6	18
232	Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study. Neuropsychopharmacology, 2016, 41, 1513-1520.	2.8	18
233	Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharmacogenetics and Genomics, 2017, 27, 143-154.	0.7	18
234	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. Biological Psychiatry, 2020, 88, 727-735.	0.7	18

#	Article	IF	Citations
235	Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. British Journal of Pharmacology, 2006, 148, 786-794.	2.7	17
236	Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls. Neuropsychopharmacology, 2013, 38, 2327-2337.	2.8	17
237	Tobacco Use Among Southwestern Alaska Native People. Nicotine and Tobacco Research, 2013, 15, 401-406.	1.4	17
238	Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. Pharmacogenetics and Genomics, 2014, 24, 172-176.	0.7	17
239	Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. Nicotine and Tobacco Research, 2015, 17, 1505-1509.	1.4	17
240	Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. Nicotine and Tobacco Research, 2018, 20, 1489-1496.	1.4	17
241	Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum. Addiction, 2018, 113, 2087-2096.	1.7	17
242	Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum. Nicotine and Tobacco Research, 2019, 21, 1706-1710.	1.4	17
243	Genome-Wide Meta-Analyses of FTND and TTFC Phenotypes. Nicotine and Tobacco Research, 2020, 22, 900-909.	1.4	17
244	Sex Differences in the Association of Cigarette Craving With Insula Structure. International Journal of Neuropsychopharmacology, 2021, 24, 624-633.	1.0	17
245	Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. BMC Public Health, 2011, 11, 741.	1.2	16
246	<scp>CHRNA</scp>5â€<scp>A</scp>3â€<scp>B</scp>4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in <scp>Alaska Native</scp> tobacco users. Addiction, 2013, 108, 1818-1828.	1.7	16
247	Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. Pharmacogenomics, 2016, 17, 405-415.	0.6	16
248	Inducing rat brain CYP2D with nicotine increases the rate of codeine tolerance; predicting the rate of tolerance from acute analgesic response. Biochemical Pharmacology, 2017, 145, 158-168.	2.0	16
249	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. Nicotine and Tobacco Research, 2018, 20, 403-413.	1.4	16
250	Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial. Annals of Behavioral Medicine, 2013, 46, 336-348.	1.7	15
251	A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. Contemporary Clinical Trials, 2016, 47, 12-21.	0.8	15
252	Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. Scientific Reports, 2017, 7, 17613.	1.6	15

#	Article	IF	Citations
253	Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. Nicotine and Tobacco Research, 2018, 20, 414-424.	1.4	15
254	Transferability of Ancestryâ€Specific and Crossâ€Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. Clinical Pharmacology and Therapeutics, 2021, 110, 975-985.	2.3	15
255	Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. European Journal of Pharmacology, 2006, 552, 151-158.	1.7	14
256	Rat brain <scp>CYP2D</scp> activity alters in vivo central oxycodone metabolism, levels and resulting analgesia. Addiction Biology, 2019, 24, 228-238.	1.4	14
257	Impact of early nausea on varenicline adherence and smoking cessation. Addiction, 2020, 115, 134-144.	1.7	14
258	Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. Nicotine and Tobacco Research, 2020, 22, 910-918.	1.4	14
259	Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse. Nicotine and Tobacco Research, 2020, 22, 1277-1284.	1.4	14
260	Fatty acid amide hydrolase binding is inversely correlated with amygdalar functional connectivity: a combined positron emission tomography and magnetic resonance imaging study in healthy individuals. Journal of Psychiatry and Neuroscience, 2021, 46, E238-E246.	1.4	14
261	Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug and Alcohol Dependence, 2014, 138, 109-117.	1.6	13
262	Intracerebroventricularly and Systemically Delivered Inhibitor of Brain CYP2B (C8-Xanthate), Even Following Chlorpyrifos Exposure, Reduces Chlorpyrifos Activation and Toxicity in Male Rats. Toxicological Sciences, 2014, 140, 49-60.	1.4	13
263	Does coffee consumption impact on heaviness of smoking?. Addiction, 2017, 112, 1842-1853.	1.7	13
264	A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 882-891.	1.1	13
265	Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e36-e40.	0.9	13
266	Impact of Menthol on Oral Nicotine Consumption in Female and Male Sprague Dawley Rats. Nicotine and Tobacco Research, 2019, 22, 196-203.	1.4	13
267	Functional connectivity of the anterior insula during withdrawal from cigarette smoking. Neuropsychopharmacology, 2021, 46, 2083-2089.	2.8	13
268	The Role of Pharmacogenetics in Smoking. Clinical Pharmacology and Therapeutics, 2021, 110, 599-606.	2.3	13
269	Designer Drugs That Are Potent Inhibitors of CYP2D6. Journal of Clinical Psychopharmacology, 2002, 22, 330-332.	0.7	12
270	Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis. International Journal of Molecular Sciences, 2013, 14, 8381-8392.	1.8	12

#	Article	IF	Citations
271	Rational design of novel CYP2A6 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 6655-6664.	1.4	12
272	Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in realâ€world settings? A prospective study. Addiction, 2019, 114, 304-314.	1.7	12
273	D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. Neuropsychopharmacology, 2020, 45, 745-752.	2.8	12
274	Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet. Advances in Nutrition, 2021, 12, 2172-2189.	2.9	12
275	Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers. Annals of Behavioral Medicine, 2012, 43, 253-261.	1.7	11
276	Relationships Between Smoking Behaviors and Cotinine Levels Among Two American Indian Populations With Distinct Smoking Patterns. Nicotine and Tobacco Research, 2018, 20, 466-473.	1.4	11
277	Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. Drug and Alcohol Dependence, 2018, 190, 72-81.	1.6	11
278	Functional Connectivity of the Raphe Nuclei: Link to Tobacco Withdrawal in Smokers. International Journal of Neuropsychopharmacology, 2018, 21, 800-808.	1.0	11
279	Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1345-1352.	1.1	11
280	Propranolol is a mechanismâ€based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6â€transgenic mice: Effects on activity and drug responses. British Journal of Pharmacology, 2020, 177, 701-712.	2.7	11
281	Association of the Fatty Acid Amide Hydrolase C385A Polymorphism With Alcohol Use Severity and Coping Motives in Heavyâ€Drinking Youth. Alcoholism: Clinical and Experimental Research, 2021, 45, 507-517.	1.4	11
282	Deficient C-oxidation of nicotine continued. Clinical Pharmacology and Therapeutics, 2001, 70, 567-567.	2.3	11
283	Designer Drugs 2.0. Clinical Pharmacology and Therapeutics, 2017, 101, 152-157.	2.3	10
284	Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. International Journal of Neuropsychopharmacology, 2018, 21, 503-512.	1.0	9
285	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Research and Treatment, 2018, 172, 371-379.	1.1	9
286	Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice. Molecular Neurobiology, 2020, 57, 2509-2520.	1.9	9
287	Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation?. Experimental and Clinical Psychopharmacology, 2017, 25, 216-222.	1.3	9
288	Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. JAMA - Journal of the American Medical Association, 2022, 327, 2201.	3.8	9

#	Article	IF	Citations
289	Neurodegenerative Diseases: A Growing Challenge. Clinical Pharmacology and Therapeutics, 2010, 88, 427-430.	2.3	8
290	DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenetics and Genomics, 2012, 22, 551-554.	0.7	8
291	The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence. Journal of Pediatric Biochemistry, 2015, 01, 105-123.	0.2	8
292	Cannabinoids: Friend or foe?. Clinical Pharmacology and Therapeutics, 2015, 97, 528-531.	2.3	8
293	Brain CYP2B induction can decrease nicotine levels in the brain. Addiction Biology, 2017, 22, 1257-1266.	1.4	8
294	The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA 2 analysis with dihydro-Î²-erythroidine. Neuropharmacology, 2017, 116, 9-17.	2.0	8
295	Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans. Data in Brief, 2019, 27, 104787.	0.5	8
296	Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. Clinical and Translational Science, 2022, 15, 204-220.	1.5	8
297	Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. Scientific Reports, 2021, 11, 19572.	1.6	8
298	Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. Nicotine and Tobacco Research, 2008, 10, 1319-1325.	1.4	7
299	Changes in Nicotine Metabolite Ratio Among Daily Smokers Receiving Treatment for Alcohol Use Disorder. Nicotine and Tobacco Research, 2020, 22, 256-263.	1.4	7
300	Long-term effectiveness of mailed nicotine replacement therapy: study protocol of a randomized controlled trial 5-year follow-up. BMC Public Health, 2018, 18, 28.	1.2	7
301	Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. Journal of the National Medical Association, 2019, 111, 509-520.	0.6	7
302	Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. Genetic Epidemiology, 2020, 44, 748-758.	0.6	7
303	The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization. Psychopharmacology, 2021, 238, 1791-1804.	1.5	7
304	Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. Nicotine and Tobacco Research, 2021, 23, 1735-1743.	1.4	7
305	Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. Drug and Alcohol Dependence, 2021, 223, 108708.	1.6	7
306	Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. Molecular Neurobiology, 2021, 58, 6540-6551.	1.9	7

#	Article	IF	Citations
307	Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia. Biochemical Pharmacology, 2022, 198, 114949.	2.0	7
308	Effects of varenicline on cognitive function in non-smokers with schizophrenia. Schizophrenia Research, 2018, 197, 562-563.	1.1	6
309	Beyond Quitting: Any Additional Impact of Mailing Free Nicotine Patches to Current Smokers?. Nicotine and Tobacco Research, 2018, 20, 654-655.	1.4	6
310	Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. Preventive Medicine, 2020, 140, 106189.	1.6	6
311	Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. Pharmacogenetics and Genomics, 2021, 31, 97-107.	0.7	6
312	The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. Brain and Behavior, 2021, 11, e01982.	1.0	6
313	Opioids: The Painful Public Health Reality. Clinical Pharmacology and Therapeutics, 2018, 103, 924-935.	2.3	5
314	Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. Drug and Alcohol Dependence, 2019, 204, 107474.	1.6	5
315	The Late Positive Potentials Evoked by Cigarette-Related and Emotional Images Show no Gender Differences in Smokers. Scientific Reports, 2019, 9, 3240.	1.6	5
316	Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice. Molecular Neurobiology, 2020, 57, 4608-4621.	1.9	5
317	Differences in propensity for drinking alcohol are reflected in subunit- and region-specific GABAA receptor levels. Addiction Biology, 1999, 4, 309-316.	1.4	4
318	Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health. Addiction, 2011, 106, 689-697.	1.7	4
319	Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. Journal of Clinical Pharmacology, 2017, 57, 230-234.	1.0	4
320	Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017). Addictive Behaviors, 2018, 79, 14-16.	1.7	4
321	The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence. Addictive Behaviors Reports, 2018, 8, 46-50.	1.0	4
322	Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. British Journal of Clinical Pharmacology, 2019, 85, 960-969.	1.1	4
323	The Influence of Tobacco Smoke/Nicotine on CYP2A Expression in Human and African Green Monkey Lungs. Molecular Pharmacology, 2020, 98, 658-668.	1.0	4
324	Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats. Brain Research Bulletin, 2020, 164, 400-406.	1.4	4

#	Article	IF	Citations
325	Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependence. Addiction Biology, 2021, 26, e12930.	1.4	4
326	Use of electronic nicotine delivery systems (ENDS) among U.S. women of reproductive age: Prevalence, reported reasons for use, and toxin exposure. Preventive Medicine, 2021, 152, 106582.	1.6	4
327	Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures. Nicotine and Tobacco Research, 2022, 24, 270-274.	1.4	4
328	Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.. Psychology of Addictive Behaviors, 2021, 35, 788-796.	1.4	4
329	Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. Advances in Pharmacology, 2022, , 73-106.	1.2	4
330	Doseâ€independent kinetics with low level exposure to nicotine and cotinine. British Journal of Clinical Pharmacology, 2013, 75, 277-279.	1.1	3
331	Nicotine Kinetics in Zebra Finches In Vivo and In Vitro. Drug Metabolism and Disposition, 2013, 41, 1240-1246.	1.7	3
332	Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. Nicotine and Tobacco Research, 2020, 22, 1419-1423.	1.4	3
333	A Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers. Nicotine and Tobacco Research, 2021, 23, 1805-1809.	1.4	3
334	Racial disparities in intensity of smoke exposure and nicotine intake among low-dependence smokers. Drug and Alcohol Dependence, 2021, 221, 108641.	1.6	3
335	Genetics of smoking behavior in American Indians. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, cebp.0026.2020.	1.1	3
336	Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and buproâ€aided smoking cessation in African Americans? A moderated mediation analysis. Addiction, 2022, 117, 1715-1724.	1.7	3
337	Brief Report: Nicotine Metabolism Ratio Increases in HIV-Positive Smokers on Effective Antiretroviral Therapy: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 428-432.	0.9	3
338	Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe. Nicotine and Tobacco Research, 2023, 25, 120-126.	1.4	3
339	Drug Addiction: A Critical Problem Calling for Novel Solutions. Clinical Pharmacology and Therapeutics, 2008, 83, 503-506.	2.3	2
340	Twenty-First-Century Neuroscience: The Potential for Innovative Therapies for Brain Disorders. Clinical Pharmacology and Therapeutics, 2012, 91, 153-157.	2.3	2
341	A Physiological Marriage Made in Heaven: Treating and Measuring the Brain Through Stimulation. Clinical Pharmacology and Therapeutics, 2019, 106, 691-695.	2.3	2
342	Five-Year Follow-up of a Randomized Clinical Trial Testing Mailed Nicotine Patches to Promote Tobacco Cessation. JAMA Internal Medicine, 2020, 180, 792.	2.6	2

#	Article	IF	Citations
343	Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial. Trials, 2020, 21, 592.	0.7	2
344	Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. Nicotine and Tobacco Research, 2020, 22, 1923-1927.	1.4	2
345	Offering nicotine patches to all households in a community with high smoking rates: Pilot test of a population-based approach to promote tobacco cessation. International Journal of Population Data Science, 2021, 6, 1400.	0.1	2
346	Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke. Clinical and Translational Science, 2021, 14, 2474-2486.	1.5	2
347	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. , 0, .		2
348	Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking. Cancers, 2021, 13, 5395.	1.7	2
349	Impact of self-reported lifetime depression or anxiety on effectiveness of mass distribution of nicotine patches. Tobacco Control, 2017, 26, 526-533.	1.8	1
350	Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. Drug and Alcohol Dependence, 2020, 210, 107967.	1.6	1
351	Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	0.7	1
352	Fatty acid amide hydrolase levels in brain linked with threat-related amygdala activation. NeuroImage Reports, 2022, 2, 100094.	0.5	1
353	Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. Nicotine and Tobacco Research, 0, , .	1.4	1
354	Brain and Disease: The Long Path to Discovery and Treatment. Clinical Pharmacology and Therapeutics, 2009, 86, 343-346.	2.3	0
355	Pharmacogenetics and Smoking Cessation. , 2019, , 499-507.		0
356	Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder. American Journal on Addictions, 2021, 30, 382-388.	1.3	0
357	Use of additional nicotine replacement therapy by participants in a five-year follow-up of a tobacco cessation trial. Addictive Behaviors, 2021, 117, 106875.	1.7	0
358	Modifying the Metabolism of Nicotine as a Therapeutic Strategy. Novartis Foundation Symposium, 0, , 235-248.	1.2	0
359	Examining the role of mitochondrial genetic variation in nicotine dependence. Psychiatry Research, 2022, 310, 114452.	1.7	0
360	Does genetic variation in a bitter taste receptor gene alter early smoking behaviours in adolescents and young adults?. Addiction, 2022, , .	1.7	0